Tharimmune shares are trading higher after the company announced the execution of an exclusive worldwide licensing agreement with Avior to develop, market and commercialize a clinical-stage asset, AV104.
Portfolio Pulse from Benzinga Newsdesk
Tharimmune has entered into an exclusive worldwide licensing agreement with Avior to develop, market, and commercialize a clinical-stage asset, AV104. This has led to an increase in Tharimmune's share price.
November 07, 2023 | 7:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tharimmune's stock price has increased following the announcement of an exclusive licensing agreement with Avior for the development of AV104.
The announcement of the exclusive licensing agreement with Avior for the development of AV104 has been positively received by the market, leading to an increase in Tharimmune's stock price. This suggests that investors are optimistic about the potential revenue and growth that this agreement could bring to Tharimmune.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100